Prostate cancer is a major health challenge with over 2 million people living with the disease across Europe. It is the most frequently diagnosed cancer among men and the third most common cause of death.1
Yet, despite the scale of the disease, prostate cancer has not received the attention that it deserves.
That’s why campaigns such as Let’s Talk Prostate Cancer, a multidisciplinary and multistakeholder initiative organised and funded by Astellas Pharma Europe Ltd, are vital to raise awareness of the impact of prostate cancer and increase its policy prioritisation across Europe.
As we build back from the COVID-19 pandemic, we must take the opportunity to transform the early diagnosis, treatment and ongoing care for men, partners and families living with prostate cancer. The time to act is now.
The LTPC campaign is led by an Expert Group representing key prostate cancer stakeholder organisations, including Europa Uomo, European Oncology Nursing Society (EONS), European Cancer Patient Coalition (ECPC), European Association of Urology (EAU), and European Association of Urology Nurses (EAUN).
- European Association of Urology (2018). Prostate cancer: recommendations to lower the risk and mortality rate of the most frequent cancer in men. Available at: https://uroweb.org/wp-content/uploads/EAU_WhitePaper_PCa_final.pdf. Last accessed October 2021
Date of prep: December 2021